{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:55:11Z","timestamp":1784876111667,"version":"3.55.0"},"reference-count":45,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.2967\/jnumed.122.265379","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T15:40:20Z","timestamp":1686238820000},"page":"1272-1278","source":"Crossref","is-referenced-by-count":11,"title":["Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen\u2013Directed Radioligand Therapy"],"prefix":"10.2967","volume":"64","author":[{"given":"Philipp E.","family":"Hartrampf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Mihatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten A.","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023080107250677000_64.8.1272.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2023080107250677000_64.8.1272.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"2023080107250677000_64.8.1272.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"2023080107250677000_64.8.1272.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"2023080107250677000_64.8.1272.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"2023080107250677000_64.8.1272.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"2023080107250677000_64.8.1272.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261982"},{"key":"2023080107250677000_64.8.1272.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023080107250677000_64.8.1272.9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023080107250677000_64.8.1272.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"issue":"5","key":"2023080107250677000_64.8.1272.11","first-page":"13N","article-title":"FDA Approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J Nucl Med."},{"key":"2023080107250677000_64.8.1272.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8850"},{"key":"2023080107250677000_64.8.1272.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.063"},{"key":"2023080107250677000_64.8.1272.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03942.x"},{"key":"2023080107250677000_64.8.1272.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.017"},{"key":"2023080107250677000_64.8.1272.16","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.ejca.2015.07.042","article-title":"High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting","volume":"51","author":"Antoun","year":"2015","journal-title":"Eur J Cancer."},{"key":"2023080107250677000_64.8.1272.17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22932"},{"key":"2023080107250677000_64.8.1272.18","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14193"},{"key":"2023080107250677000_64.8.1272.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2016.04.001"},{"key":"2023080107250677000_64.8.1272.20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41391-019-0186-6","article-title":"Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia","volume":"23","author":"Stangl-Kremser","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023080107250677000_64.8.1272.21","doi-asserted-by":"crossref","first-page":"e0122047","DOI":"10.1371\/journal.pone.0122047","article-title":"Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One."},{"key":"2023080107250677000_64.8.1272.22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int."},{"key":"2023080107250677000_64.8.1272.23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/pros.24088","article-title":"CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer","volume":"81","author":"Sheikhbahaei","year":"2021","journal-title":"Prostate."},{"key":"2023080107250677000_64.8.1272.24","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.25","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.26","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","article-title":"mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/pros.24414","article-title":"Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy","volume":"82","author":"Hartrampf","year":"2022","journal-title":"Prostate."},{"key":"2023080107250677000_64.8.1272.28","doi-asserted-by":"crossref","unstructured":"Hartrampf PE Weinzierl FX Serfling SE . Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T. Cancers (Basel). 2022;14:647.","DOI":"10.3390\/cancers14030647"},{"key":"2023080107250677000_64.8.1272.29","doi-asserted-by":"crossref","unstructured":"Hartrampf PE Heinrich M Seitz AK . Metabolic tumour volume from PSMA PET\/CT scans of prostate cancer patients during chemotherapy: do different software solutions deliver comparable results? J Clin Med. 2020;9:1390.","DOI":"10.3390\/jcm9051390"},{"key":"2023080107250677000_64.8.1272.30","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"key":"2023080107250677000_64.8.1272.31","doi-asserted-by":"publisher","DOI":"10.1002\/wics.1460"},{"key":"2023080107250677000_64.8.1272.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103496"},{"key":"2023080107250677000_64.8.1272.33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/CIA.S6920","article-title":"Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update","volume":"5","author":"Waters","year":"2010","journal-title":"Clin Interv Aging."},{"key":"2023080107250677000_64.8.1272.34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/01635581.2021.1884731","article-title":"Nutritional status and health-related quality of life in men with advanced castrate-resistant prostate cancer","volume":"74","author":"Cavka","year":"2022","journal-title":"Nutr Cancer."},{"key":"2023080107250677000_64.8.1272.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262671"},{"key":"2023080107250677000_64.8.1272.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263274"},{"key":"2023080107250677000_64.8.1272.37","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22531"},{"key":"2023080107250677000_64.8.1272.38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2023080107250677000_64.8.1272.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2023080107250677000_64.8.1272.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231431"},{"key":"2023080107250677000_64.8.1272.41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","article-title":"PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.43","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023080107250677000_64.8.1272.44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023080107250677000_64.8.1272.45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/aja.aja_53_20","article-title":"Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review","volume":"23","author":"Chen","year":"2021","journal-title":"Asian J Androl."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T14:29:37Z","timestamp":1690900177000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.2967\/jnumed.122.265379"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265379","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}